Compare Tapestry, Inc. (TPR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tapestry, Inc. vs Zoetis Inc — how do they compare? Tapestry, Inc. trades at $140.62 (market cap $28.51B), while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: Tapestry, Inc. and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| TPR | ZTS | |
|---|---|---|
Market Cap | $28.51B | $31.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $160.49 | $156.76 |
52-Week Low | $95.69 | $71.91 |
Enterprise Value | $31.37B | $39.24B |
Dividend Yield | 1.13% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TPR trades at $142.16, up 0.49% today, with a neutral technical signal but strong fundamental momentum after three consecutive quarterly earnings beats. The stock carries high valuation ratios, including a P/E of 43.02, but demonstrates robust profitability with a 76.18% gross margin and 55.74% ROE. Recent corporate news includes the appointment of Jonathan Saunders as Kate Spade's Executive Creative Director, signaling brand revitalization efforts.
Outlook remains positive with a consensus price target of $183.88, implying 29% upside, supported by 75.6% analyst buy ratings. Key risks include elevated debt levels and margin compression from 2024's 12.23% to 2025's 2.61% net income margin. Investors should weigh strong brand positioning against valuation sensitivity and cyclical retail exposure.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
